AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SEATTLE -- Women who used active estrogen-progestin therapy in the Women's Health Initiative continued to have a reduced rate of bone fracture during the first year after the trial was halted. Rebecca D. Jackson, M.D., said at the annual meeting of the American Society for Bone and Mineral Research.
There has been concern that when hormone therapy (HT) is stopped, bone loss might start up again at an accelerated rate, particularly among women with a low body mass index (BMI). The study shows that this is not the case.
During the follow-up period, in which 9,380 of the study participants were surveyed twice (at 6 months and 1 year), the total fracture rate among the women who had been assigned to active treatment was 25% lower than among those who had received placebo. The rate of hip fracture, specifically, was 27% lower, said Dr. Jackson of the division of endocrinology at Ohio State University, Columbus.
The rate of total fractures among the women who had been on HT was 14.9 per 1,000 patient-years; that compared with a rate of 20.8 among those who had been on placebo. The rates of hip fracture ...
Source: HighBeam Research, No rapid bone loss seen in year after HT is stopped: still have a...